Affiliation:
1. Kazan State Medical University; City Clinical Hospital № 7
2. Kazan State Medical University
3. Kazan State Medical University; Children’s Republican Clinical Hospital
4. City Clinical Hospital № 7
Abstract
Aim. To assess the detection rate of familial hypercholesterolemia among outpatients visiting a lipidologist.Material and methods. We analyzed the causes and nature of lipid metabolism disorders in patients of the Adult Lipidology Center as follows: 1233 people aged 18-84, including 777 women (63,02%) and 456 men (36,98%). Biomaterial samples from 421 patients with the phenotype of definite, possible or probable familial hypercholesterolemia were studied by massive parallel sequencing using a panel of 5 genes associated with familial hypercholesterolemia (LDLR, LDLRAP1, APOB, APOE, PCSK9). For statistical processing, descriptive statistics methods were used.Results. Working-age patients apply 1,56 times more often than patients of the older age group (60,91% vs 39,09%), and the vast majority of them were referred by a primary care physician based on data from periodic health examinations. The mean level of total cholesterol and low-density lipoprotein cholesterol in the lipidology center was 7,58 and 4,8, respectively. Out of 421 samples, 127 patients (10,3% of the total number of patients and 30,16% of the number of biosamples) had previously described variants of the LDLR, APOB and/or PCSK9 genes associated with familial hypercholesterolemia.Conclusion. The detection rate of definite familial hypercholesterolemia ranges from 5,51 to 8,43% of outpatients visiting a lipidologist, while the proportion of verified carriers of gene mutations related to familial hypercholesterolemia is 10,3%. The diagnosis should not be rejected with a formally low probability according to the S. Broom and DLCN criteria, as well as when identifying data suggestive of secondary lipid metabolism disorders.
Subject
Cardiology and Cardiovascular Medicine
Reference13 articles.
1. Ezhov MV, Bazhan SS, Ershova AI, et al. Clinical guidelines for familial hepercholesterolemia. Ateroscleroz. 2019;15(1):58-98. (In Russ.)
2. Ezhov MV, Barbarash OL, Voevoda MI, et al. Organization of lipid centers operation in the Russian Federation — new opportunities. Russian Journal of Cardiology. 2021;26(6):4489. (In Russ.) doi:10.15829/1560-4071-2021-4489.
3. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Inter J Cardiol. 2014;171:309-25. doi:10.1016/j.ijcard.2013.11.025.
4. Karpov YuA, Kukharchuk VV, Boytsov SA. Consensus Statement of the Russian National Atherosclerosis Society (RNAS) Familial hypercholesterolemia in Russia: outstanding issues in diagnosis and management. Ateroskleroz I dislipidemias. 2015;2:5-16. (In Russ.)
5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.